Zsuzsanna
Zsuzsanna BerÉnyi, Debrecen HU
Patent application number | Description | Published |
---|---|---|
20140296173 | STABLE NANOCOMPOSITION COMPRISING EPIRUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both; (ii) an active compound selected from the group of epirubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, metal ion and stabilizer/formulating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
Zsuzsanna Birkó, Debrecen HU
Patent application number | Description | Published |
---|---|---|
20120015361 | Oligonucleotides For The Detection Of Aspergillus Species - The invention relates to oligonucleotides that are specific for the fungi belonging to | 01-19-2012 |
Zsuzsanna Bösze, Godollo HU
Patent application number | Description | Published |
---|---|---|
20100041743 | TRANSGENIC ANIMAL WITH ENHANCED IMMUNE RESPONSE AND METHOD FOR THE PREPARATION THEREOF - The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins. | 02-18-2010 |
20130109087 | Transgenic Animal with Enhanced Immune Response and Method for the Preparation Thereof | 05-02-2013 |
Zsuzsanna Bösze, Godollo HU
Patent application number | Description | Published |
---|---|---|
20100041743 | TRANSGENIC ANIMAL WITH ENHANCED IMMUNE RESPONSE AND METHOD FOR THE PREPARATION THEREOF - The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins. | 02-18-2010 |
Zsuzsanna Csikos, Nyirbator HU
Patent application number | Description | Published |
---|---|---|
20140099266 | MAGNETIC FLUID NANOSYSTEM - Targeting contrast agent for magnetic resonance imaging (MRI). In preferred embodiments, self-assembled polyelectrolytes coated superparamagnetic iron oxide contrast agent particles are provided, which are labeled with targeting moieties, afforded enhanced relaxivity, improved signal-to-noise and targeting ability. Accordingly, the invention relates to a stable targeting contrast nanosystem applicable for magnetic resonance imaging (MRI) having at least one nanoparticle polyelectrolyte polyanion; a targeting agent conjugated to the biopolymer; and a superparamagnetic ligand. In another embodiment the nanosystem according to the invention has at least two biocompatible and biodegradable nanoparticle polyelectrolyte biopolymer. Particularly, the superparamagnetic iron oxide particles are coated by a polyelectrolyte biopolymer and this system self-assembles with the other biopolymer to produce stable nanosystem for magnetic resonance imaging. Targeting moieties are conjugated to a biopolymer or to the self-assembled biopolymers to realize a targeted delivery of contrast agent. Methods for making these targeting MRI contrast agents are also provided. | 04-10-2014 |
20140294966 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both or to the surface of the nanoparticle; (ii) an active compound selected from the group of docetaxel and its pharmaceutically acceptable salts and derivatives especially its hydrates, especially docetaxel trihydrate and docetaxel trihydrate monohydrochloride; and optionally (iii) at least one complexing agent, a metal ion and a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
20140294983 | STABLE NANOCOMPOSITION COMPRISING DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both, or to the surface of the nanoparticle; (ii) an active compound selected from the group of doxorubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, a metal ion, a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
Zsuzsanna Dorko, Milwaukee, WI US
Patent application number | Description | Published |
---|---|---|
20110283785 | Testing Method and Kit for Detecting Lead, Mercury, and Chromate in Paint , Varnish, and Other surface Coatings - A testing kit and method of testing for the presence of lead mercury and chromate in surface coatings is provided that can accurately determine the presence of lead, mercury and chromate in the surface coating without interference from other constituents of the surface coating. The kit includes an alkaline caustic that is utilized to dissolve the coating material to enable any lead or mercury present in the coating material to react with a subsequently added second solution containing sulfide ions, while preventing interference of other ionic species with the interaction of the lead and sulfide. The sulfide ions can then react with the lead or mercury in order to produce a dark color for the resulting solution. The resulting color can then be compared against a color standard to determine the amount of lead or mercury present in the sample. The kit and method also enables a determination for the presence of chromate by dissolving the coating material in the alkaline solution and observing the development of a characteristic pale yellow color. | 11-24-2011 |
Zsuzsanna Evinger, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090221823 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES - The present invention is related to 1-[(4-chlorophenyl)-phenylmethyl]-4-(2,2,2-trichloroethoxycarbonyl)-piperazine of the Formula (IV) and optically isomers thereof, process for preparation thereof and the use of the compound of the Formula (IV) in the preparation of 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers and salts thereof. 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers thereof are important intermediates in the preparation of non-sedating antihistamine-type active pharmaceutical ingredients. | 09-03-2009 |
Zsuzsanna Izsvak, Berlin DE
Patent application number | Description | Published |
---|---|---|
20110117072 | HYPERACTIVE VARIANTS OF THE TRANSPOSASE PROTEIN OF THE TRANSPOSON SYSTEM SLEEPING BEAUTY - The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed. | 05-19-2011 |
Zsuzsanna Kuklenyik, Lawrenceville, GA US
Patent application number | Description | Published |
---|---|---|
20130210031 | DETECTION OF ADENYLATE CYCLASE - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples. | 08-15-2013 |
Zsuzsanna Szamosvolgyi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20150073004 | SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula 1 | 03-12-2015 |
Zsuzsanna Szent-Kirallyi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20090137563 | PROCESS FOR THE PREPARTION OF OLANZAPINE - The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno [2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno [2,3-b][1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound. | 05-28-2009 |
20120178729 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT - The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis. | 07-12-2012 |
20120330018 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS - The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof. | 12-27-2012 |
Zsuzsanna Szent-Királlyi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20120330018 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS - The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof. | 12-27-2012 |
Zsuzsanna Takatsy, Budapest HU
Patent application number | Description | Published |
---|---|---|
20140051103 | PROCEDURE FOR BIPHASIC PREPARATION OF LIPOSOMES AND APPLICATION THEREOF IN MANUFACTURING DIAGNOSTIC REAGENTS - The invention relates to a procedure for biphasic preparation of liposomes, in the course of which technically simple and cheap mechanical mixing methods are used to commingle non-polar organic phase containing an individual mixture of natural and synthetic phospholipids and polar aqueous (buffer) phase not miscible with it, resulting in a liposome emulsion of a unique structure. Furthermore, the invention comprises embodiments of the procedure related to the in vitro diagnostic use of liposomes prepared in this way, when protein type active components are anchored to the surface of liposome membranes without application of any detergents and non-protein type active components are simply mixed with the liposome emulsion of a unique structure. In one of the possible embodiments of the procedure a Prothrombin Time (PT) reagent is prepared. Another possible embodiment of the procedure is the preparation of an activated partial thromboplastin time (APTT) reagent. | 02-20-2014 |
Zsuzsanna Tomoskozi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20110059964 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS - The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof. | 03-10-2011 |
20140288106 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula 1 | 09-25-2014 |
20150073004 | SUBSTITUTED B-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula 1 | 03-12-2015 |
Zsuzsanna Varvasovsky-Hutton, Coppet CH
Patent application number | Description | Published |
---|---|---|
20150040294 | BELT WITH AUTOGENOUS CLOSURE SYSTEM - The present invention provides a belt with an autogenous closure system. The autogenous closure system includes a length of belt strap, and a retainer means that is at least partially affixed to or formed from the belt strap. The retainer means can be a continuous piece of material with one or more slits cut into it to form two or more retainer elements adjacent to each other, or it can comprise two or more separate retainer strips. In operation, the tongue end of the belt strap is threaded through the retainer strips or retainer elements, forming a U-shaped bend around the edge of the retainer element that is furthest from the base of the belt strap and then passing through an aperture formed by the retainer element closer to the base. A method of manufacturing a belt with an autogenous closure system is also provided. | 02-12-2015 |